Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer

  • Yuksel, Ozgur Haki (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital) ;
  • Urkmez, Ahmet (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital) ;
  • Akan, Serkan (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital) ;
  • Yldirim, Caglar (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital) ;
  • Verit, Ayhan (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital)
  • Published : 2015.10.06


Purpose: To predict prostatic carcinoma using a logistic regression model on prebiopsy peripheral blood samples. Materials and Methods: Data of a total of 873 patients who consulted Urology Outpatient Clinics of Fatih Sultan Mehmet Training and Research Hospital between February 2008 and April 2014 scheduled for prostate biopsy were screened retrospectively. PSA levels, prostate volumes, prebiopsy whole blood cell counts, neutrophil and platelet counts, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), biopsy results and Gleason scores in patients who had established diagnosis of prostate cancer (PCa) were evaluated. Results: This study was performed on a total of 873 cases, with an age range 48-76 years, divided into three groups as for biopsy results. with diagnoses of benign prostatic hyperplasia (BPH) (n=304, 34.8 %), PCa (n=265, 30.4 %) and histological prostatitis (n=304; 34.8 %). Intra- and intergroup comparative evaluations were performed. White blood cell and neutrophil counts in the histological prostatitis group were significantly higher than those of the BPH and PCa groups (p=0.001; p=0.004; p<0.01). A statistically significant intergroup difference was found for PLR (p=0.041; p<0.05) but not lymphocyte count (p>0.05). According to pairwise comparisons, PLR were significantly higher in the PCa group relative to BPH group (p=0.018, p<0.05, respectively). Though not statistically significant, higher PLR in cases with PCa in comparison with the prostatitis group was remarkable (p=0.067, and p>0.05, respectively). Conclusions: Meta-analyses showed that in patients with PSA levels over 4 ng/ml, positive predictive value of PSA is only 25 percent. Therefore, novel markers which can both detect clinically significant prostate cancer, and also prevent unnecessary biopsies are needed. Relevant to this issue in addition to PSA density, velocity, and PCA3, various markers have been analyzed. In the present study, PLR were found to be the additional predictor of prostatic carcinoma.


Prostatic carcinoma;PSA;platelet-to-lymphocyte ratio;neutrophil-to-lymphocyte ratio


  1. Fujita K, Hosomi M, Nakagawa M, et al (2014). White blood cell count is positively associated with benign prostatic hyperplasia. Int J Urol, 21, 308-2.
  2. Fujita K, Imamura R, Tanigawa G, et al (2012). Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis, 15, 386-0.
  3. Gorelick C, Andikyan V, Mack M, Lee YC, Abulafia (2009). Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an innercity population. Int J Gynecol Cancer, 19, 1384-9.
  4. Gueron G, De Siervi A, Vazquez E (2012). Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis, 15, 213-1
  5. Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009). The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet, 279, 53-6.
  6. Jarnicki A, Putoczki T, Ernst M (2010). Stat3: linking inflammation to epithelial cancer more than a "gut" feeling? Cell Div, 5, 14.
  7. Kantoff PW, Higano CS, Shore ND, et al (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363, 411-2.
  8. Karazanashvili G (2008). Editorial comment on: the relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol, 54, 1383-4.
  9. Keizman D, Gottfried M, Ish-Shalom M, et al (2012). Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistantprostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist, 17, 1508-4.
  10. Kerpsack JT, Finan MA (2000). Thrombocytosis as a predictor of malignancy in women with a pelvic mass. J Reprod Med, 45, 929-2.
  11. Kramer G, Mitteregger D, Marberger M (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol, 51, 1202-6.
  12. Li AJ, Madden AC, Cass I, et al (2004). The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol, 92, 211-4.
  13. Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancerrelated inflammation. Nature, 454, 436-4.
  14. McDonald AC, Vira MA, Vidal AC, et al (2014). Association between systemic inflammatory markers and serum prostatespecific antigen in men without prostatic disease - the 2001-2008 national health and nutrition examination survey. Prostate, 74, 561-7.
  15. Mengus C, Le Magnen C, Trella E, et al (2011). Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med, 9, 162.
  16. Mistry K, Cable G (2003). Meta-analysis of prostatespecific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract, 16, 95-1.
  17. Nuhn P, Vaghasia AM, Goyal J, et al (2013). Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castrationresistantprostate cancer (mCRPC) treated with first-line docetaxel. BJU Int, e-pub ahead of print, doi: 10.1111/bju.12531.
  18. Palapattu GS, Sutcliffe S, Bastian PJ, et al (2005). Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis, 26, 1170-1.
  19. Pond GR, Armstrong AJ, Wood BA, et al (2012). Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int, 110, 461-8.
  20. Prins RC, Rademacher BL, Mongoue-Tchokote S, et al (2012). C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol, 30, 33-7.
  21. Roehl KA, Antenor JA, Catalona WJ (2002). Serial biopsy results in prostate cancer screening study. J Urol, 167, 2435-9.
  22. Schaider H, Oka M, Bogenrieder T, et al (2003). Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer, 103, 335-3.
  23. Shafique K, Proctor MJ, McMillan DC, et al (2012). Systemic inflammation and survival of patients with prostate cancer: evidence from the glasgow inflammation outcome study. Prostate Cancer Prostatic Dis, 15, 195-1.
  24. Shafique K, Proctor MJ, McMillan DC, et al (2013). The modified glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer, 13, 292.
  25. Sonpavde G, Pond GR, Armstrong AJ, et al (2014). Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer, 12, 317-4.
  26. Sumbul AT, Sezer A, Abali H, et al (2014). Neutrophil-tolymphocyte ratio predicts PSA response, but notoutcomes in patients with castration-resistant prostate cancer treated withdocetaxel. Int Urol Nephrol, 46, 1531-5.
  27. Tai CG, Johnson TV, Abbasi A, et al (2014). External validation of the modified glasgow prognostic score for renal cancer. Indian J Urol, 30, 33-7.
  28. Tanik S, Albayrak S, Zengin K, et al (2014). Is the neutrophillymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pac J Cancer Prev, 15, 6375-9.
  29. Templeton AJ, Pezaro C, Omlin A, et al (2014). Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer, 120, 3346-2.

Cited by

  1. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy vol.16, pp.1, 2016,
  2. Predictive value of neutrophil-to-lymphocyte ratio in diagnosis of prostate cancer among men who underwent template-guided prostate biopsy vol.95, pp.44, 2016,
  3. Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer pp.08878013, 2017,
  4. A Case of Prostatic Carcinoma Manifesting as Cutaneous Facial Nodule vol.2018, pp.2090-6978, 2018,
  5. Platelet-lymphocyte ratio (PLR) and all-cause mortality in general population: insights from national health and nutrition education survey pp.1369-1635, 2019,